Savara Inc (SVRA) shareholders
Close on Nov 17, 2026Market cap $920.46MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anthony A. Florence, Jr. Joint filing with Ali Behbahani (12.00%), Carmen Chang (12.00%) and 10 more | 24,471,264 | 12.00% | 13D (active) amendment | Nov 12, 2025 |
| VHCP Management III, LLC Joint filing with Bong Y. Koh (9.90%), Nimish Shah (9.90%) and 4 more | 20,881,288 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (9.99%), Dreyfuss, Philip D. (9.99%) and 15 more | 18,288,986 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| BCLS II Investco, LP Joint filing with BCIP Life Sciences Associates, LP (9.99%), Bain Capital Life Sciences Fund II, L.P. (9.99%) | 17,600,621 | 9.99% | 13D (active) amendment | Mar 25, 2025 |
| Giauque, Nicolas Joint filing with Wehrly, Mark C. (6.90%), Dreyfuss, Philip D. (6.90%) and 13 more | 15,000,000 | 6.90% | 13G (passive) amendment | Dec 31, 2025 |
| Deerfield Management Company, L.P. Joint filing with Deerfield Mgmt, L.P. (6.74%), Deerfield Partners, L.P. (6.74%) and 1 more | 13,569,000 | 6.74% | 13G (passive) | Oct 30, 2025 |
| Chen Yu Joint filing with TCG Crossover Fund I, L.P. (6.10%), TCG Crossover GP I, LLC (6.10%) | 12,362,205 | 6.10% | 13G (passive) amendment | Dec 31, 2025 |
| Patrick J. Heron Joint filing with James N. Topper (6.60%), Albert Cha (5.60%) and 1 more | 11,462,301 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 10,957,322 | 5.40% | 13G (passive) | Dec 31, 2025 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (6.30%) | 10,775,000 | 6.30% | 13G (passive) | Dec 31, 2024 |
| Nimish Shah Joint filing with Bong Y. Koh (5.20%), VHCP Co-Investment Holdings III, LLC (5.20%) and 4 more | 9,021,507 | 5.20% | 13G (passive) | Jun 30, 2025 |
| Adage Capital Partners GP, L.L.C. Joint filing with Adage Capital Management, L.P. (5.64%), Adage Capital Partners, L.P. (5.64%) and 2 more | 7,637,930 | 5.64% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SVRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 24,471,264 | 11.91% | $150.74M | – | 9.49% |
| Bain Capital Life Sciences Investors, LLC | 17,600,621 | 8.57% | $108.42M | – | 6.45% |
| VR Adviser, LLC | 14,745,943 | 7.18% | $90.84M | +1,005,568 | 2.75% |
| Nantahala Capital Management, LLC | 13,953,620 | 6.79% | $85.95M | +6,608,837 | 1.43% |
| Deerfield Management Company, L.P. (Series C) | 13,569,000 | 6.60% | $83.59M | – | 0.87% |
| BlackRock, Inc. | 12,494,498 | 6.08% | $76.97M | +1,203,313 | 0.00% |
| TCG Crossover Management, LLC | 12,362,205 | 6.02% | $76.15M | – | 1.83% |
| Frazier Life Sciences Management, L.P. | 9,720,852 | 4.73% | $59.88M | – | 1.30% |
| Polar Capital Holdings Plc | 9,541,786 | 4.64% | $58.78M | – | 0.14% |
| Vanguard Capital Management LLC | 7,932,545 | 3.86% | $48.86M | +148,632 | 0.00% |
| State Street Corp | 6,553,348 | 3.19% | $40.37M | −154,336 | 0.00% |
| Marshall Wace, Llp | 6,256,989 | 3.05% | $38.54M | +1,742,641 | 0.03% |
| Rtw Investments, LP | 5,952,380 | 2.90% | $36.67M | – | 0.31% |
| Woodline Partners LP | 4,245,119 | 2.07% | $26.15M | – | 0.08% |
| Orbimed Advisors LLC | 3,959,900 | 1.93% | $24.39M | +3,324,900 | 0.45% |
| Geode Capital Management, LLC | 3,872,133 | 1.88% | $23.86M | +277,653 | 0.00% |
| Spruce Street Capital LP | 3,452,576 | 1.68% | $21.27M | +69,401 | 4.17% |
| Rosalind Advisors, Inc. | 3,178,121 | 1.55% | $19.58M | −25,600 | 7.27% |
| Emerald Advisers, LLC | 3,148,439 | 1.53% | $19.39M | −222,846 | 0.46% |
| Pictet Asset Management Holding SA | 2,763,055 | 1.34% | $17.02M | +487,674 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 224M | 100.0% | 25 / 71 | 57 / 26 | 19M | 7M |
| Q1 2026 | 186 | 212M | 100.0% | 61 / 63 | 38 / 21 | 30M | 9M |
| Q4 2025 | 148 | 201M | 97.9% | 41 / 52 | 41 / 13 | 55M | 16M |
| Q3 2025 | 126 | 163M | 79.4% | 24 / 41 | 43 / 20 | 15M | 19M |
| Q2 2025 | 123 | 168M | 81.6% | 13 / 48 | 36 / 26 | 13M | 10M |
| Q1 2025 | 136 | 165M | 80.4% | 21 / 50 | 38 / 19 | 17M | 14M |
| Q4 2024 | 135 | 163M | 79.3% | 31 / 50 | 32 / 18 | 24M | 21M |
| Q3 2024 | 126 | 161M | 78.1% | 18 / 56 | 27 / 23 | 29M | 15M |
| Q2 2024 | 133 | 155M | 75.2% | 32 / 59 | 27 / 18 | 45M | 12M |
| Q1 2024 | 120 | 122M | 59.2% | 32 / 46 | 25 / 9 | 12M | 12M |
| Q4 2023 | 98 | 122M | 59.4% | 25 / 37 | 16 / 11 | 20M | 15M |
| Q3 2023 | 84 | 117M | 56.8% | 19 / 38 | 16 / 12 | 32M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
126 funds held SVRA in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SVRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,164,961 | 3.00% | $37.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,003,124 | 1.95% | $24.66M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,196,119 | 1.56% | $19.69M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,672,858 | 0.81% | $9.13M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,555,905 | 0.76% | $9.58M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,436,801 | 0.70% | $8.85M | 0.06% | Jun 30, 2026 |
| SmallCap Growth Fund I | 932,020 | 0.45% | $5.09M | 0.20% | Jul 31, 2026 |
| Emerald Growth Fund | 798,875 | 0.39% | $4.36M | 0.29% | Jul 31, 2026 |
| Emerald Growth Fund | 798,875 | 0.39% | $4.19M | 0.30% | Apr 30, 2026 |
| Vanguard Russell 2000 Index Fund | 752,873 | 0.37% | $3.91M | 0.02% | May 31, 2026 |
| iShares Biotechnology ETF | 752,380 | 0.37% | $4.63M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 704,716 | 0.34% | $3.66M | 0.01% | May 31, 2026 |
| F/m Emerald Life Sciences Innovation ETF | 651,024 | 0.32% | $3.39M | 3.22% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 646,784 | 0.31% | $3.36M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 511,820 | 0.25% | $3.15M | 0.21% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Pauls | CHIEF EXECUTIVE OFFICER, Director | 1,188,050 | 0.58% | Dec 16, 2025 |
| Braden C. Parker | Chief Commercial Officer | 75,677 | 0.04% | Sep 25, 2026 |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 328,977 | 0.16% | Jul 24, 2026 |
| David L. Lowrance | Chief Financial Officer | 953,968 | 0.46% | Jun 22, 2026 |
| Kathleen R. McCabe | Chief Legal Officer | 519,232 | 0.25% | Dec 16, 2025 |
| Anne Erickson | Chief Business Officer | 371,712 | 0.18% | Dec 16, 2025 |
| Yasmine Wasfi | Chief Medical Officer | 168,008 | 0.08% | Dec 4, 2025 |
| Raymond Dennis Pratt | Chief Medical Officer | 340,050 | 0.17% | Dec 16, 2024 |
| Joseph S. McCracken | Director | 302,644 | 0.15% | Feb 17, 2026 |
| David A. Ramsay | Director | 2,533,642 | 1.23% | Dec 19, 2025 |
| Richard J. Hawkins | Director | 161,326 | 0.08% | Dec 11, 2025 |
| Es-Johansson An van | Director | 102,500 | 0.05% | Dec 11, 2025 |
| Nevan C. Elam | Director | 106,887 | 0.05% | Dec 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Braden C. Parker Chief Commercial Officer | Sep 24, 2026 | Tax withholding | −29,323 | $5.07 | $148.67K | 75,677 |
| Robert Matthew Lutz Chief Fin. & Operating Officer | Jul 15, 2026 | Award | +35,000 | – | – | 328,977 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +218,750 | $1.51 | $330.31K | 953,968 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −53,387 | $5.50 | $293.63K | 930,560 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +87,650 | $3.35 | $293.63K | 983,947 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −10,114 | $5.50 | $55.63K | 896,297 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +12,500 | $4.45 | $55.63K | 906,411 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −60,057 | $5.50 | $330.31K | 893,911 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Sale | −394,528 | $5.68 | $2.24M | 536,032 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −11,491 | $5.50 | $63.20K | 735,218 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +56,937 | $1.11 | $63.20K | 746,709 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −28,928 | $5.50 | $159.10K | 689,772 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +129,350 | $1.23 | $159.10K | 718,700 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −21,682 | $5.50 | $119.25K | 589,350 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +75,000 | $1.59 | $119.25K | 611,032 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +75,000 | $1.59 | $119.25K | 417,555 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −24,174 | $5.04 | $121.84K | 342,555 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +80,684 | $1.51 | $121.83K | 366,729 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −9,485 | $5.04 | $47.80K | 526,237 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +43,063 | $1.11 | $47.80K | 535,722 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −11,037 | $5.04 | $55.63K | 527,700 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +24,850 | $3.35 | $83.25K | 552,550 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −16,518 | $5.04 | $83.25K | 536,032 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −23,661 | $5.04 | $119.25K | 393,894 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +130,650 | $1.23 | $160.70K | 524,544 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −31,885 | $5.04 | $160.70K | 492,659 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +12,500 | $4.45 | $55.63K | 538,737 |
| Joseph S. McCracken Director | Feb 16, 2026 | Option exercise | +1,807 | $1.76 | $3.18K | 302,644 |
| David A. Ramsay Director | Dec 19, 2025 | Sale | −20,000 | $6.06 | $121.20K | 2,533,642 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2025 | Gift | −128,995 | – | – | 1,188,050 |
| David L. Lowrance Chief Financial Officer | Dec 16, 2025 | Gift | −32,000 | – | – | 286,045 |
| Anne Erickson Chief Business Officer | Dec 14, 2025 | Tax withholding | −62,960 | $6.92 | $435.68K | 371,712 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 14, 2025 | Tax withholding | −195,705 | $6.92 | $1.35M | 1,317,045 |
| David L. Lowrance Chief Financial Officer | Dec 14, 2025 | Tax withholding | −62,960 | $6.92 | $435.68K | 318,045 |
| Robert Matthew Lutz Chief Operating Officer | Dec 14, 2025 | Tax withholding | −67,760 | $6.92 | $468.90K | 293,977 |
| Kathleen R. McCabe Chief Legal Officer | Dec 14, 2025 | Tax withholding | −39,350 | $6.92 | $272.30K | 519,232 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2025 | Gift | −23,629 | – | – | 1,512,750 |
| Nevan C. Elam Director | Dec 9, 2025 | Award | +40,000 | – | – | 106,887 |
| David A. Ramsay Director | Dec 9, 2025 | Award | +40,000 | – | – | 2,553,642 |
| Es-Johansson An van Director | Dec 9, 2025 | Award | +40,000 | – | – | 102,500 |
| Joseph S. McCracken Director | Dec 9, 2025 | Award | +40,000 | – | – | 300,837 |
| Richard J. Hawkins Director | Dec 9, 2025 | Award | +40,000 | – | – | 161,326 |
| Yasmine Wasfi Chief Medical Officer | Dec 4, 2025 | Tax withholding | −21,992 | $6.37 | $140.09K | 168,008 |
| Nevan C. Elam Director | Dec 2, 2025 | Option exercise | +5,860 | $1.46 | $8.56K | 68,360 |
| Nevan C. Elam Director | Dec 2, 2025 | Tax withholding | −1,473 | $5.81 | $8.56K | 66,887 |
| Richard J. Hawkins Director | Nov 14, 2025 | Option exercise | +5,860 | $1.46 | $8.56K | 121,326 |
| Yasmine Wasfi Chief Medical Officer | Oct 20, 2025 | Award | +35,000 | – | – | 190,000 |
| Richard J. Hawkins Director | Jun 20, 2025 | Buy | +48,225 | $2.04 | $98.38K | 115,466 |
| Joseph S. McCracken Director | May 29, 2025 | Buy | +10,000 | $2.08 | $20.80K | 260,837 |
| David A. Ramsay Director | Mar 31, 2025 | Buy | +150,000 | $2.78 | $417.00K | 2,513,642 |
| Robert Matthew Lutz Chief Operating Officer | Feb 13, 2025 | Tax withholding | −38,263 | $2.83 | $108.28K | 361,737 |
| David L. Lowrance Chief Financial Officer | Dec 16, 2024 | Sale | −25,000 | $3.33 | $83.25K | 381,005 |
| Richard J. Hawkins Director | Dec 16, 2024 | Sale | −8,000 | $3.32 | $26.56K | 67,241 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Sale | −54,702 | $3.31 | $181.06K | 1,536,379 |
| David L. Lowrance Chief Financial Officer | Dec 13, 2024 | Gift | −12,000 | – | – | 430,355 |
| David L. Lowrance Chief Financial Officer | Dec 13, 2024 | Tax withholding | −24,350 | $3.21 | $78.16K | 406,005 |
| Anne Erickson Chief Business Officer | Dec 13, 2024 | Tax withholding | −18,263 | $3.21 | $58.62K | 434,672 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 13, 2024 | Tax withholding | −92,593 | $3.21 | $297.22K | 1,591,081 |
| Braden C. Parker Chief Commercial Officer | Dec 12, 2024 | Award | +20,000 | – | – | 105,000 |
| Es-Johansson An van Director | Dec 12, 2024 | Award | +40,000 | – | – | 62,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Savara's stock actually held short. Settlement fails (shares not delivered on time) peaked at 519,414 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David L. Lowrance Officer | Jun 22, 2026 | 394,528 | $2.23M | Jun 22, 2026 | Cashless Stock Option Exercise |
| David A. Ramsay Director | Dec 18, 2025 | 20,000 | $122.20K | Dec 18, 2025 | Board Compensation |
| David L. Lowrance Officer | Dec 16, 2024 | 25,000 | $82.50K | Dec 16, 2024 | Vesting of RSU's |
| Matthew Pauls Director | Dec 16, 2024 | 54,702 | $180.80K | Dec 16, 2024 | Vesting of RSU's |
| Richard J. Hawkins Director | Dec 16, 2024 | 8,000 | $26.30K | Dec 16, 2024 | Vesting of RSU |
| Nevan C. Elam Director | Dec 28, 2023 | 93,843 | $448.57K | Dec 28, 2023 | CASH EXERCISE |
| Matthew Pauls Officer, Director | Dec 28, 2023 | 84,000 | $398.00K | Dec 28, 2023 | Vesting of RSU |
| David L. Lowrance Officer | Dec 28, 2023 | 10,000 | $47.40K | Dec 28, 2023 | VESTING OF RESTRICTED STOCK UNIT |
See a number that looks wrong?